NASDAQ:ACCD Accolade (ACCD) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ACCD Stock Alerts $7.89 -1.30 (-14.15%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$7.62▼$8.5650-Day Range$7.89▼$12.3652-Week Range$6.33▼$17.00Volume1.49 million shsAverage Volume728,244 shsMarket Capitalization$610.75 millionP/E RatioN/ADividend YieldN/APrice Target$15.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accolade alerts: Email Address Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside87.6% Upside$14.80 Price TargetShort InterestHealthy4.06% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment-0.17Based on 24 Articles This WeekInsider TradingSelling Shares$73,872 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsBusiness Services Sector63rd out of 310 stocksBusiness Services, Not Elsewhere Classified Industry29th out of 89 stocks 4.4 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAccolade has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Accolade has recently decreased by 2.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 1.0 News and Social Media Coverage News SentimentAccolade has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Accolade this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,872.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.33) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesApril 26, 2024 | markets.businessinsider.comAccolade’s Hold Rating Affirmed Amid Conservative Outlook and Adjusted Financial EstimatesApril 26, 2024 | markets.businessinsider.comAccolade’s Hold Rating Affirmed Amid Revenue Growth Uncertainty and Earnings VolatilityApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 26, 2024 | finance.yahoo.comAccolade Inc (ACCD) Q4 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic ...April 25, 2024 | sfgate.comAccolade: Fiscal Q4 Earnings SnapshotApril 25, 2024 | msn.comACCD Stock Earnings: Accolade Misses EPS, Beats Revenue for Q4 2024April 25, 2024 | finance.yahoo.comAccolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ...April 25, 2024 | globenewswire.comAccolade Announces Results for Fiscal Fourth Quarter and Full Year 2024April 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 24, 2024 | investing.comStifel cuts Accolade stock price target to $13, maintains buy ratingApril 23, 2024 | finance.yahoo.comAccolade, Inc. (ACCD)April 23, 2024 | americanbankingnews.comAccolade (NASDAQ:ACCD) Price Target Cut to $13.00 by Analysts at Stifel NicolausApril 22, 2024 | benzinga.comAlphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For MondayApril 21, 2024 | investing.comAccolade CEO Rajeev Singh sells $3.1k in stockApril 18, 2024 | morningstar.comAccolade Inc Ordinary SharesApril 18, 2024 | americanbankingnews.comAccolade (ACCD) Scheduled to Post Quarterly Earnings on ThursdayApril 14, 2024 | uk.investing.comAccolade CFO exercises options, sells shares for tax obligationsApril 5, 2024 | seekingalpha.comAccolade: Staying Bullish On Favorable DevelopmentsApril 3, 2024 | finance.yahoo.comAccolade to Announce Fiscal Fourth Quarter 2024 Financial ResultsApril 1, 2024 | finance.yahoo.comRecent uptick might appease Accolade, Inc. (NASDAQ:ACCD) institutional owners after losing 24% over the past yearMarch 20, 2024 | prnewswire.comAccolade Wins 2024 Artificial Intelligence Excellence AwardMarch 19, 2024 | businesswire.comNational Accolade Bestowed on Arkansas-Based Provider: ‘Best Rural High Speeds'March 19, 2024 | prnewswire.comAccolade Promotes Kelsi McDonald Harris to Chief People OfficerMarch 17, 2024 | finance.yahoo.comACCD Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comACCD Apr 2024 12.500 callMarch 15, 2024 | barrons.comAccolade Inc.March 12, 2024 | proactiveinvestors.comChesapeake Bank receives AARP accolade for combatting financial exploitationSee More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today4/26/2024Next Earnings (Estimated)7/04/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,370Year FoundedN/APrice Target and Rating Average Stock Price Target$14.80 High Stock Price Target$19.00 Low Stock Price Target$11.00 Potential Upside/Downside+96.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-459,650,000.00 Net Margins-31.59% Pretax Margin-31.48% Return on Equity-27.27% Return on Assets-14.36% Debt Debt-to-Equity Ratio0.48 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$363.14 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value$6.51 per share Price / Book1.21Miscellaneous Outstanding Shares77,410,000Free Float70,983,000Market Cap$610.76 million OptionableOptionable Beta2.08 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 56)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 55)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 52)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 45)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 49)Executive VP, General Counsel, CCO & Secretary Ms. Kelsi McDonald HarrisChief People Officer & Senior Vice PresidentMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsInternational Money ExpressNASDAQ:IMXIViadNYSE:VVIConduentNASDAQ:CNDTPaysafeNYSE:PSFELiquidity ServicesNASDAQ:LQDTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 2,000 shares on 4/25/2024Ownership: 0.000%Sumitomo Mitsui Trust Holdings Inc.Sold 104,934 shares on 4/19/2024Ownership: 2.193%Rajeev SinghSold 355 sharesTotal: $3,131.10 ($8.82/share)Stephen H BarnesSold 109 sharesTotal: $961.38 ($8.82/share)Robert N CavanaughSold 141 sharesTotal: $1,243.62 ($8.82/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions Should I buy or sell Accolade stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price target for 2024? 16 equities research analysts have issued 12 month target prices for Accolade's stock. Their ACCD share price targets range from $11.00 to $19.00. On average, they anticipate the company's share price to reach $14.80 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2024? Accolade's stock was trading at $12.01 on January 1st, 2024. Since then, ACCD stock has decreased by 34.3% and is now trading at $7.89. View the best growth stocks for 2024 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ACCD earnings forecast. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) posted its quarterly earnings results on Thursday, April, 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The business earned $124.80 million during the quarter, compared to analysts' expectations of $123.91 million. Accolade had a negative net margin of 31.59% and a negative trailing twelve-month return on equity of 27.27%. The firm's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) EPS. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT), Global X Millennial Consumer ETF (MILN) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Accolade issued on next quarter's earnings? Accolade updated its first quarter 2025 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $103.0 million-$106.0 million, compared to the consensus revenue estimate of $110.9 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? Accolade (ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.19%), Los Angeles Capital Management LLC (0.07%), Simplex Trading LLC (0.00%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACCD) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.